Opin vísindi

Browsing by Subject "Augndropar"

Browsing by Subject "Augndropar"

Sort by: Order: Results:

  • Icon
    Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy? 
    Johannesson, Gauti; Gottfredsdottir, Maria; Ásgrimsdóttir, Guðrún Marta; Loftsson, Thorsteinn; Stefánsson, Einar (Wiley, 2020-02-17)
    Purpose: Compare (a) nonmitomycin C (MMC) trabeculectomy and 1.5% dexamethasone nanoparticle (DexNP) eye drops postoperatively with (b) trabeculectomy with MMC and Maxidex® eye drops postoperatively. Methods: Randomized prospective single masked clinical ...
  • Icon
    Cyclodextrin nanoparticles for targeted ocular drug delivery of kinase inhibitors 
    Praphanwittaya, Pitsiree (University of Iceland, School of Health Sciences, Faculty of Pharmaceutical Sciences, 2020-11)
    Background: Age-related macular degeneration (AMD) causes vision loss in elderly people due to neovascularization. The first line treatments are intravitreal injections which can induce severe pain. Oral administration still produces side effects. ...
  • Icon
    In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation 
    Lorenzo Veiga, Blanca; Diaz-Rodriguez, Patricia; Alvarez-Lorenzo, Carmen; Loftsson, Thorsteinn; Sigurdsson, Hakon Hrafn (MDPI AG, 2020-04-09)
    The aim of this study was to design and evaluate novel cyclodextrin (CD)-based aggregate formulations to efficiently deliver nepafenac topically to the eye structure, to treat inflammation and increase nepafenac levels in the posterior segment, thus ...
  • Icon
    Ocular drug delivery with topical administration 
    Lorenzo Soler, Laura (University of Iceland, School of Health Sciences, Faculty of Medicine, 2022-11-01)
    Fyrir marga lyfjaflokka þykir staðbundin lyfjagjöf í augndropaformi ákjósanlegasta leiðin vegna einfaldleika við lyfjagjöf. Eru augndropar algengasta aðferðin til að meðhöndla augnsjúkdóma í fremri hluta augans. Staðbundin lyfjagjöf í augndropaformi ...